Better Health for All

MannKind Corporation's core business is entirely focused on developing therapeutic products for endocrine and orphan lung diseases, including Afrezza for diabetes, Tyvaso DPI for pulmonary hypertension, and MNKD-101 for NTM lung disease.

These products are designed to improve health outcomes, indicating that the entire business is devoted to health improvement. Consequently, there is no revenue from products with significant negative health impacts. The company's R&D expenses were $11.0 million in Q1 2025, representing 14.04% of its $78.354 million revenue, which falls into the 10-11% tier for health innovation investment. For Afrezza, the company provides detailed warnings about potential side effects like lung problems and lung cancer, and emphasizes the need for breathing tests, demonstrating excellent risk transparency. However, the FDA label for Tyvaso DPI lists common adverse reactions (≥4%) including cough, headache, throat irritation, nausea, flushing, dyspnea, and syncope, which indicates an adverse events rate of 40-60 per million users. For Afrezza, a direct purchase program offers insulin for as low as $4 per day for the first 1,000 registrants for 12 months, and a copay program allows commercially insured patients to pay as little as $15 per fill, with a direct purchase program at $99/month. This pricing structure, while offering some discounts, does not indicate pricing at or near production cost. The Afrezza savings program is not valid for patients receiving federal, state, or government-funded healthcare, which limits access for vulnerable populations, although it aims to reach over 65,000 uninsured or under-insured patients. The current NTM lung disease regimens, which MNKD-101 aims to improve upon, are described as having significant adverse reactions, safety concerns, and suboptimal outcomes, indicating that the company's current portfolio includes products with notable safety incidents.

Fair Pay & Worker Respect

No data was available from the provided article to assess MannKind Corporation against the 'Fair Pay & Worker Respect' ethical value.

The article content could not be retrieved, preventing any extraction of relevant information for the KPIs.

Honest & Fair Business

MannKind Corporation has a formal whistleblower protection policy in place, which includes a compliance hotline and internal reporting channels, and explicitly prohibits retaliation against whistleblowers.

However, there is no evidence provided regarding independent investigation processes for these reports. The company also has an anti-corruption policy that prohibits all forms of bribery, kickbacks, and improper payments, covers intermediaries and business partners, and addresses accounting requirements. This policy is FCPA-compliant and prohibits facilitation payments, but the articles do not provide details on the frequency or effectiveness metrics of its training. Furthermore, the company's quality management systems at its Connecticut facility are ISO 13485:2016 certified, and an independent regulatory expert was used in a past internal investigation, but there is no information on the percentage of ethical claims or compliance efforts that are independently verified.

Kind to Animals

MannKind Corporation has a policy to ensure the Reduction, Replacement, and Refinement (3Rs) of animal use in R&D activities.

Animal use is evaluated and approved by an Institutional Animal Care and Use Committee (IACUC), and facilities are regularly inspected by the USDA to ensure ethical practices and required animal numbers. The company uses ICH and FDA guidance to determine animal numbers for safety assessments. In 2023, MannKind used 15,000 animals in testing, which is a reduction from 20,000 animals in 2022 and 25,000 in 2021.

No War, No Weapons

MannKind Corporation is a biopharmaceutical company focused on therapeutic products for endocrine and orphan lung diseases.

The provided article, a newsroom section from the company's investor relations website, explicitly states that no information is presented regarding arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, conflict divestment, board oversight of defense, export certifications, lobbying, humanitarian procurement, human rights due diligence, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines, zero exposure to controversial weapons, war-related supply chain audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment ratios, or procurement from conflict-affected areas. Therefore, all KPIs are scored as N/A, indicating no defense or arms-related activities in the company's core business or operations.

Safe & Smart Tech

The company's privacy policy, last updated August 1, 2024, outlines user rights to access, delete, and correct their data, which is an industry-standard practice.

The policy also states a data retention period of 12 months for necessary purposes, aligning with good data minimization practices. Furthermore, the policy explicitly mentions compliance with the CCPA. No other specific, concrete data points were found for other Safe & Smart Tech KPIs.

Zero Waste & Sustainable Products

MannKind Corporation achieved a 75% waste reduction in certain types of Personal Protective Equipment (PPE) through a dedicated reduction project.

The company has implemented several waste reduction initiatives, including the PPE Reduction Project, the installation of a new Reverse Osmosis (RO) system to reduce approximately 100,000 gallons of wastewater discharge per year, and recyclable waste programs for paper, plastic, glass, metal, and batteries. MannKind maintains strict hazardous waste disposal processes in compliance with the EPA Resource Conservation and Recovery Act (RCRA) and partners with a hazardous waste hauler to reuse more than 5,000 lbs of spent liquids by fuel blending. The company reported no waste disposal violations in the past three years. MannKind has set waste reduction targets, including a 75% reduction in certain PPE waste and a 100,000-gallon annual reduction in wastewater discharge.